IDEAYA Biosciences, Inc.
$3.29B- Market cap
- $3.85B
- Debt
- +$84.13M
- Cash
- −$639.39M
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: IDYA stock price at premium vs PCG $39.86 current versus $3.48 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PCG's multiple
Implied fair value · at IDYA's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · PCG FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 15.05x
Capital structure 40% equity / 60% debt · EV / Revenue 3.84x · EV / EBITDA 18.83x
PCG carries the larger enterprise value at $95.82B against $3.29B; PCG trades on the lower EV / Revenue multiple (3.84x vs 15.05x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
PG&E CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
1.79x
Net debt / EBITDA
Leverage against operating earnings
4.97x
11.30x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$713.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
SEMPRA
IDYA vs SRE
Duke Energy CORP
IDYA vs DUK
COMCAST CORP
IDYA vs CMCSA
DTE ENERGY CO
IDYA vs DTE
PUBLIC SERVICE ENTERPRISE GROUP INC
IDYA vs PEG
NATIONAL FUEL GAS CO
IDYA vs NFG
$84.13M
$58.21B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.